PART1 and hsa-miR-429-Mediated SHCBP1 Expression Is an Independent Predictor of Poor Prognosis in Glioma Patients

Abstract

Gliomas are the most common primary brain tumors. Because of their high degree of malignancy, patient survival rates are unsatisfactory. Therefore, exploring glioma biomarkers will play a key role in early diagnosis, guiding treatment, and monitoring the prognosis of gliomas. We found two lncRNAs, six miRNAs, and nine mRNAs that were differentially expressed by analyzing genomic data of glioma patients. The diagnostic value of mRNA expression levels in gliomas was determined by receiver operating characteristic (ROC) curve analysis. Among the nine mRNAs, the area under the ROC curve values of only CEP55 and SHCBP1 were >0.7, specifically 0.834 and 0.816, respectively. Additionally, CEP55 and SHCBP1 were highly expressed in glioma specimens and showed increased expression according to the glioma grade, and outcomes of high expression patients were poor. CEP55 was enriched in the cell cycle, DNA replication, mismatch repair, and P53 signaling pathway. SHCBP1 was enriched in the cell cycle, DNA replication, ECM receptor interaction, and P53 signaling pathway. Age, grade, IDH status, chromosome 19/20 cogain, and SHCBP1 were independent factors for prognosis. Our findings suggest the PART1-hsa-miR-429-SHCBP1 regulatory network plays an important role in gliomas.

Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis

“…GSE108474 ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi ) contains 671 samples, which included 21 cases of non-tumor tissue, 2 WHO grade I gliomas, 99 WHO grade II gliomas, 84 WHO grade III gliomas, 134 grade WHO IV gliomas, and 331 without tissue grade ( Table 1 ). The WHO classification system was used according to our previous descriptions [ 6 , 20 ]. All data comes from public databases (GTEx, TCGA, GSE108474) and is completely anonymous.…”

“…To explore the relationship between the risk model and common clinical traits, we analyzed the relationship between the risk model and these common clinical traits, such as ATRX status, Chr 19/20 co-gain, Chr 7 gain/Chr 10 loss, MGMT promoter status, 1P/19q co-deletion, IDH status, mutation count, histology, gender, grade, age and fustat (state of existence) [ 20 ]. We found that the risk model is related to all clinical traits except gender.…”

“…1). The WHO classification system was used according to our previous descriptions [6,20]. All data comes from public databases (GTEx, TCGA, GSE108474) and is completely anonymous.…”

lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis

“…At present, PART1, as a novel lncRNA, has been associated with tumor progression, metastasis and chemotherapy resistance ( 22 , 23 ). In addition, PART1 has been found to be involved in the regulation of several signaling pathways, such as the PTEN/AKT signaling pathway ( 24 ), the microRNA (miR)-150-5p/LRG1 axis ( 22 ) and the miR-429/SHCBP1 regulatory network ( 25 ), suggesting that targeting PART1 may be a novel and promising therapeutic strategy in patients with cancer. Therefore, elucidation of the function of PART1 and its molecular mechanisms, may provide further understanding and enable treatment in a clinical setting for different types of cancer.…”

<p>Ropivacaine Inhibits Cell Proliferation, Migration and Invasion, Whereas Induces Oxidative Stress and Cell Apoptosis by circSCAF11/miR-145-5p Axis in Glioma</p>

“…2,3 Although much attempt has been focused on the glioma treatment, the 5 years survival rate is still unsatisfactory. 4 Ropivacaine, one of the safest local anesthetics, is widely used in cancer therapy. 5,6 Ropivacaine works via repressing the voltage-gated sodium channels.…”